Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MIRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMIRA secures worldwide exclusive rights to MIRA-55 and SKNY-1 programs under amended license
Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
MIRA obtained worldwide exclusive rights to develop, manufacture, sell, and sublicense products under intellectual property covering its MIRA-55 and SKNY-1 development programs through an amended agreement with Miralogx.
Item 1.01 verify on EDGAR → -
medium
The amended license agreement does not materially change the core economic terms previously disclosed, suggesting financial obligations remain substantially unchanged.
Item 1.01 verify on EDGAR → -
low
Company publicly announced the license agreement execution via press release on June 4, 2026, one day after signing.
Item 7.01 verify on EDGAR →
Summary
MIRA Pharmaceuticals amended its exclusive license agreement with Miralogx on June 3, 2026, securing worldwide rights to intellectual property underlying two key development programs: MIRA-55 and SKNY-1. The agreement grants MIRA full commercial rights including development, manufacturing, sales, and sublicensing capabilities globally.
Importantly, the company disclosed that core economic terms remain materially unchanged from the prior arrangement, indicating this is primarily a structural refinement rather than a fundamental renegotiation. For retail investors, this filing confirms MIRA's control over its two main pipeline assets and removes potential uncertainty about IP ownership or licensing constraints.
The worldwide scope is particularly significant as it eliminates geographic limitations on commercialization. Since economic terms are unchanged, there should be no surprise impact on cash flow or milestone payment obligations. Investors should watch for updates on clinical progress for MIRA-55 and SKNY-1, as the value of these exclusive rights depends entirely on successful development. The next catalyst will likely be trial data or regulatory milestones for either program.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 3, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) entered into an Amended and Restated Exclusive License Agreement (the “License Agreement”) with MIRALOGX LLC (“Miralogx”).
The Company entered into an amended and restated exclusive license agreement with Miralogx on June 3, 2026. This replaces or updates a prior license arrangement between the parties.
Event · Item 7.01 — Regulation FD Disclosure
Company executed a License Agreement and issued a press release announcing the transaction.
Added in current filing · verify on EDGAR →
On June 4, 2026, the Company issued a press release announcing the execution of the License Agreement.
The company executed a License Agreement and publicly announced it via press release on June 4, 2026.The press release (Exhibit 99.1) would contain those material details but is not included in the body text provided.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The information set forth under Item 7.01 and in Exhibit 99.1 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
This is standard boilerplate language for Item 7.01 disclosures under Regulation FD. It means the information is being "furnished" rather than "filed," which limits legal liability and prevents automatic incorporation into other SEC filings. This is procedural and does not affect the substance of the License Agreement disclosure.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Amended and Restated Exclusive License Agreement, by and between the Company and MIRALOGX LLC dated June 3, 2026
The company entered into an amended and restated exclusive license agreement with MIRALOGX LLC on June 3, 2026. The 8-K does not provide details on what terms changed or the nature of the licensed intellectual property, but the amendment and restatement of an exclusive license agreement could materially affect the company's rights, obligations, or commercialization strategy.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify